Metformin suppresses hepatocellular carcinoma cell growth through induction of cell cycle G1/G0 phase arrest and p21CIP and p27KIP expression and downregulation of cyclin D1 in vitro and in vivo

Oncology Reports

Volumn 30, Issue 5, 2013, Pages 2449-2457

  Cai, Xianbin ^a   Hu, Xi ^a   Cai, Bozhi ^a   Wang, Qinjia ^a   Li, Youfeng ^a   Tan, Xiaojun ^a   Hu, Hui ^a   Chen, Xiaofeng ^a   Huang, Jiexiong ^a   Cheng, Jidong ^a   Jing, Xubin ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

AMP activated protein kinase activation; Cell cycle arrest; Hepatocellular carcinoma; Metformin

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; ENZYME PHOSPHORYLATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; MORBIDITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; UPREGULATION;

AMINOIMIDAZOLE CARBOXAMIDE; ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL SURVIVAL; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; METFORMIN; MICE; RIBONUCLEOTIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84885078113     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2718     Document Type: Article

References (40)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Bosch FX, Ribes J, Díaz M and Cléries R: Primary liver cancer: worldwide incidence and trends. Gastroenterology 127 (Suppl 1): S5-S16, 2004.
3. Altekruse SF, McGlynn KA and Reichman ME: Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 27: 1485-1491, 2009.
4. Chen DS: Hepatocellular carcinoma in Taiwan. Hepatol Res 37 (Suppl 2): S101-S105 2007.
5. Hundal RS, Krssak M, Dufour S, et al: Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 49: 2063-2069, 2000.
6. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD and Evans JM: New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 32: 1620-1625, 2009.
7. Bowker SL, Majumdar SR, Veugelers P and Johnson JA: Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29: 254-258, 2006.
8. Gotlieb WH, Saumet J, Beauchamp MC, et al: In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol Oncol 110: 246-250, 2008.
9. Zhang ZJ, Zheng ZJ, Shi R, Su Q, Jiang Q and Kip KE: Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis. J Clin Endocrinol Metab 97: 2347-2353, 2012.
10. Vernon G, Baranova A and Younossi ZM: Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 34: 274-285, 2011.
11. Starley BQ, Calcagno CJ and Harrison SA: Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 51: 1820-1832, 2010.
12. Baig NA, Herrine SK and Rubin R: Liver disease and diabetes mellitus. Clin Lab Med 21: 193-207, 2001.
13. Giovannucci E, Harlan DM, Archer MC, et al: Diabetes and cancer: a consensus report. CA Cancer J Clin 60: 207-221, 2010.
14. Stickel F and Hellerbrand C: Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma: mechanisms and implications. Gut 59: 1303-1307, 2010.
15. Hardie DG: Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology 144: 5179-5183, 2003.
16. Kyriakis J: At the crossroads: AMP-activated kinase and the LKB1 tumor suppressor link cell proliferation to metabolic regulation. J Biol 2: 26, 2003.
17. Baas AF, Kuipers J, van der Wel NN, et al: Complete polarization of single intestinal epithelial cells upon activation of LKB1 by STRAD. Cell 116: 457-466, 2004.
18. Corradetti MN, Inoki K, Bardeesy N, DePinho RA and Guan KL: Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. Genes Dev 18: 1533-1538, 2004.
19. Slattery ML and Fitzpatrick FA: Convergence of hormones, inflammation, and energy-related factors: a novel pathway of cancer etiology. Cancer Prev Res 2: 922-930, 2009.
20. Liu J, Li M, Song B, et al: Metformin inhibits renal cell carcinoma in vitro and in vivo xenograft. Urol Oncol 31: 264-270, 2013.
21. Schneider MB, Matsuzaki H, Haorah J, et al: Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterology 120: 1263-1270, 2001.
22. Zhuang Y and Miskimins WK: Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1. J Mol Signal 3: 18, 2008.
23. Rattan R, Graham RP, Maguire JL, Giri S and Shridhar V: Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo. Neoplasia 13: 483-491, 2011.
24. Algire C, Amrein L, Zakikhani M, Panasci L and Pollak M: Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase. Endocr Relat Cancer 17: 351-360, 2010.
25. Zakikhani M, Dowling RJO, Sonenberg N and Pollak MN: The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Res 1: 369-375, 2008.
26. Yasmeen A, Beauchamp MC, Piura E, Segal E, Pollak M and Gotlieb WH: Induction of apoptosis by metformin in epithelial ovarian cancer: involvement of the Bcl-2 family proteins. Gynecol Oncol 121: 492-498, 2011.
27. Hassan MM, Curley SA, Li D, et al: Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer 116: 1938-1946, 2010.
28. Chen HP, Shieh JJ, Chang CC, et al: Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut 62: 606-615, 2013.
29. Ouyang J, Parakhia RA and Ochs RS: Metformin activates AMP kinase through inhibition of AMP deaminase. J Biol Chem 286: 1-11, 2011.
30. Bhalla K, Hwang BJ, Dewi RE, et al: Metformin prevents liver tumorigenesis by inhibiting pathways driving hepatic lipogenesis. Cancer Prev Res 5: 544-552, 2012.
31. Xiong Y, Lu QJ, Zhao J and Wu GY: Metformin inhibits growth of hepatocellular carcinoma cells by inducing apoptosis via mitochondrion-mediated pathway. Asian Pac J Cancer Prev 13: 3275-3279, 2012.
32. Qu Z, Zhang Y, Liao M, Chen Y, Zhao J and Pan Y: In vitro and in vivo antitumoral action of metformin on hepatocellular carcinoma. Hepatol Res 42: 922-933, 2012.
33. Nielsen NH, Arnerlöv C, Emdin SO and Landberg G: Cyclin E overexpression, a negative prognostic factor in breast cancer with strong correlation to oestrogen receptor status. Br J Cancer 74: 874-880, 1996.
34. Biliran HJ, Wang Y, Banerjee S, et al: Overexpression of cyclin D1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an elastase-myc transgene-expressing pancreatic tumor cell line. Clin Cancer Res 11: 6075-6086, 2005.
35. Polyak K, Kato JY, Solomon MJ, et al: p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev 8: 9-22, 1994.
36. Cheng F, McLaughlin P, Verderame M and Zagon I: The OGF-OGFr axis utilizes the p21 pathway to restrict progression of human pancreatic cancer. Mol Cancer 7: 5, 2008.
37. Cayrol C, Knibiehler M and Ducommun B: p21 binding to PCNA causes G1 and G2 cell cycle arrest in p53-deficient cells. Oncogene 16: 311-320, 1998.
38. Gardner LB, Li Q, Park MS, Flanagan WM, Semenza GL and Dang CV: Hypoxia inhibits G1/S transition through regulation of p27 expression. J Biol Chem 276: 7919-7926, 2001.
39. Toyoshima H and Hunter T: p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 78: 67-74, 1994.
40. Weinberg RA: The retinoblastoma protein and cell cycle control. Cell 81: 323-330, 1995.